Bryan Garnier - MEDINCELL (MED.PA) MEDINCELL: Mdc-WWM (contraception) moves forward with the support of the BMGF | BUY | EUR10.3 vs. EUR10 (+48%)

Report

Bryan Garnier

Eric Le Berrigaud

MEDINCELL: Mdc-WWM (contraception) moves forward with the support of the BMGF | BUY | EUR10.3 vs. EUR10 (+48%)

MEDINCELL - BUY | EUR10.3 vs. EUR10 (+48%)
Mdc-WWM (contraception) moves forward with the support of the BMGF

MedinCell to receive up to USD19m in grants
Another validation of the technology
MedinCell is holding rights in developed markets
FV adjustment to the cash received

29/11/2019 3 EN

Underlying

MEDINCELL

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

Bryan Garnier

MEDINCELL: Interim read-out for mdc-IRMâ€™s phase III delayed into H2 2020 | BUY | EUR9.7 vs. EUR10.3

MEDINCELL - BUY | EUR9.7 vs. EUR10.3 (+30%) Interim read-out for mdc-IRMâ€™s phase III delayed into H2 2020 Unsurprising first-half numbers Status update for mdc-IRM: a difficult-to-interpret new delay What does it mean? We need to adjust our FV

December 4, 2019 December 4, 2019 3 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 17.57

November 25, 2019 November 25, 2019 14 EN

Planisware: in line, but cautious

This morning, Planisware published its Q1 2025 results, which were mostly in line with consensus along with our estimates. Group top-line came in at EUR47.5m, up 14.3% at constant currency, and 1% above company-compiled consensus. Growth was mainly driven by recurring revenues, up 16.2% at constant

4h / 13m 4h / 13m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

BioInvent Q1: Making steady progress, key readouts ahead

BioInvent reported Q1'25 results which mainly focused on balance sheet items and a recap of corporate achievements for the quarter, with opex roughly in line with our estimates at SEK(144.8m) (runway mid-2026). Importantly, several key upcoming catalysts have been reiterated for mid-2025 on both le

4h / 13m 4h / 13m 1 EN

Cedric Rossi

Cedric Rossi

adidas: Strong Q1 and FY25 outlook confirmed despite the tariff hurdle

Unsurprisingly, definitive Q1 2025 results unveiled this morning are in line with last week's pre-release (23rd April), which showed strong sales momentum, +17% FX-n ex-Yeezy, and better-than-expected margin delivery. Albeit reassuring against the highly fluid tariff backdrop and macro uncertainty,

4h / 19m 4h / 19m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDINCELL: Mdc-WWM (contraception) moves forward with the support of the BMGF | BUY | EUR10.3 vs. EUR10 (+48%)

MEDINCELL: Interim read-out for mdc-IRMâ€™s phase III delayed into H2 2020 | BUY | EUR9.7 vs. EUR10.3

Feasibility Study Results in December to be a Catalyst for this Junior

Planisware: in line, but cautious

BioInvent Q1: Making steady progress, key readouts ahead

adidas: Strong Q1 and FY25 outlook confirmed despite the tariff hurdle

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe